Immunomagnetic Nanocapsule Targeted Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly immunotherapy using immune checkpoint inhibitors, face challenges such as time-consuming processes, limited effectiveness due to cancer cell mutation, and adverse autoimmune reactions, along with inefficiencies in delivering micron-sized structures through the bloodstream to target cancer cells.
Innovation Solution
Development of immunomagnetic nanocapsules composed of a core encapsulated in a shell formed by fucoidan, oxidized dextran, and superparamagnetic iron oxide nanoparticles, with antibodies immobilized on the outer layer, allowing for targeted delivery and enhanced tumor inhibition with reduced antibody dosage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If micron-sized microbeads are used to mimic antigen presenting cells for T cell proliferation, then T cell training can be achieved, but the microbeads cannot be circulated into the target area via human blood due to their large size
Solution Approach 1:
The patent changes the size parameter of the carrier from micron-sized (microbeads) to nanosized (50-200 nm), enabling circulation through human blood vessels while maintaining the ability to function as antigen presenting cells for T cell proliferation and training
Solution Approach 2:
The patent creates a composite nanocarrier structure comprising a core-shell design where the shell is formed by a complex of fucoidan, oxidized dextran, and superparamagnetic iron oxide nanoparticles, combining multiple materials to achieve both circulation capability and immunological function
2Reliability
If immune checkpoint inhibitors are used to activate the immune system, then anti-cancer ability is enhanced, but autoimmune reactions such as skin ulcers and gastrointestinal ulcers occur
Solution Approach 1:
The patent applies local quality by functionalizing the nanocarrier surface with specific antibodies (anti-CD3, anti-CD28, anti-CD40) that selectively interact with immune cells, and by using a biocompatible core-shell structure that locally delivers immune checkpoint inhibitors to tumor sites while minimizing systemic autoimmune reactions
Solution Approach 2:
The patent introduces the nanocarrier as an intermediary that delivers immune checkpoint inhibitors and T cell expansion antibodies in a controlled manner, mediating between the immune system and cancer cells while reducing harmful autoimmune side effects through targeted delivery
3Reliability
If current immunotherapy methods are used, then immune cells can be obtained and cultured, but the process is time consuming and the returned immune cells lose their effect due to cancer cell mutation
Solution Approach 1:
The patent applies preliminary action by pre-functionalizing the nanocarrier with T cell expansion antibodies (anti-CD3, anti-CD28, anti-CD40) and immune checkpoint inhibitors before administration, enabling immediate in vivo T cell activation and proliferation without requiring lengthy in vitro culture processes
Solution Approach 2:
The patent enables self-service by designing the nanocarrier to autonomously deliver multiple immunotherapeutic agents (T cell expansion antibodies and immune checkpoint inhibitors) simultaneously, allowing the patient's own immune system to be activated and proliferate T cells in vivo without external laboratory intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunomagnetic nanocapsules improve anti-cancer effects by achieving better tumor inhibition with lower antibody doses and extending the half-life of the treatment, while minimizing autoimmune reactions and improving immune cell targeting, as demonstrated in breast and colorectal cancer models.
Implementation Method 1
The shell is formed by a complex, and the complex is fabricated by a combination of fucoidan, oxidized dextran, and a plurality of superparamagnetic iron oxide nanoparticles via a hydrophobic interaction
Implementation Method 2
a plurality of superparamagnetic iron oxide nanoparticles
Data Source
AI summary
An immunomagnetic nanocapsule includes a core, a shell and an outer layer. The shell is formed by a complex, and the complex is fabricated by a combination of fucoidan, oxidized dextran, and a plurality of superparamagnetic iron oxide nanoparticles via a hydrophobic interaction. The core is encapsulated in the shell. The outer layer includes at least one antibody immobilized to outside of the shell to form the outer layer, wherein the antibody is an immune checkpoint inhibitor and/or a T cell expansion antibody.